Imvexxy (Estradiol) Patent Expiration, LOE Window & CMS Spending

Imvexxy (Estradiol) by Mayne: FDA Orange Book LOE 2034-02-02, 1 AB generics, $14.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMayne
FDA Application & PathwayN208564 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-02-02
Orange Book Patents (*PED Extensions)20 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$14.8M
2024 Medicare Part D Spend$13.7M
2024 Medicaid Spend$1.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel